Efficacy and safety of direct oral anticoagulants compared with heparin for preventing thromboembolism in hospitalized patients with COVID-19: a systematic review …
Y Tian, T Pan, X Wen, G Ao, Y Ma… - Clinical and Applied …, 2023 - journals.sagepub.com
A high rate of thromboembolism and a high risk of death have been reported regarding
hospitalized patients with coronavirus disease 2019 (COVID-19). Recently, we noticed that …
hospitalized patients with coronavirus disease 2019 (COVID-19). Recently, we noticed that …
COVID-19 thromboprophylaxis. New evidence
R Ferrandis, P Sierra, A Gomez-Luque - Revista Española de …, 2023 - Elsevier
Recent publications have questioned the efficacy of using therapeutic or intermediate doses
of low molecular weight heparin in COVID-19 patients, especially in the most severe …
of low molecular weight heparin in COVID-19 patients, especially in the most severe …
Antiplatelet therapy prior to COVID-19 infection impacts on patients mortality: a propensity score-matched cohort study
M Sokolski, K Reszka, B Adamik, K Kilis-Pstrusinska… - Scientific Reports, 2024 - nature.com
One of the major pathomechanisms of COVID-19 is the interplay of hyperinflammation and
disruptions in coagulation processes, involving thrombocytes. Antiplatelet therapy (AP) by …
disruptions in coagulation processes, involving thrombocytes. Antiplatelet therapy (AP) by …
Direct Oral Anticoagulants' Consumption and Expenditure in the COVID-19 Pandemic in Russia and Clinical Practice Guidelines for Their Use
EA Baybulatova, MS Chenkurov, EA Korovyakova… - …, 2023 - mdpi.com
Background: The coronavirus pandemic has led to the creation of clinical guidelines by a
large number of professional medical communities. However, the quality and methodology …
large number of professional medical communities. However, the quality and methodology …
Tromboprofilaxis en COVID-19. Nuevas evidencias
R Ferrandis, P Sierra, A Gomez-Luque - Revista Española de …, 2023 - Elsevier
Recientes publicaciones han puesto en duda la eficacia de la utilización de dosis
terapéuticas o intermedias de heparina de bajo peso molecular (HBPM) en pacientes …
terapéuticas o intermedias de heparina de bajo peso molecular (HBPM) en pacientes …
Factor Xa inhibitors versus low molecular weight heparin for preventing coagulopathy following COVID-19: a systematic review and meta analysis of randomized …
L Amin, K Qayyum, M Uzair, F Khan… - Annals of Medicine …, 2024 - journals.lww.com
Background: Hospitalized patients with COVID-19 have shown a significant occurrence of
thromboembolism and a heightened risk of death. It remains unclear whether factor Xa …
thromboembolism and a heightened risk of death. It remains unclear whether factor Xa …
Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic
We compliment Gómez et al. 1 for reporting their large retrospective, multicenter, nationwide
study that investigated the risk factors associated with mortality and poor prognosis in …
study that investigated the risk factors associated with mortality and poor prognosis in …